{
    "id": "college_medicine-101",
    "question": "Alterations in which neurotransmitters in the brain by pharmacological agents has been shown to influence fatigue development?",
    "options": {
        "A": "Acetyl choline and noradrenaline.",
        "B": "Dopamine and acetyl choline.",
        "C": "Glutamate and serotonin.",
        "D": "Dopamine and serotonin."
    },
    "answer": "D",
    "predict": "To answer this question, let's break down the key points related to fatigue and neurotransmitters from the provided documents. 1. **Understanding Fatigue**: Fatigue is a complex symptom with multiple causes, including biochemical, behavioral, and physiological factors. It's not solely related to a single neurotransmitter or mechanism. 2. **Neurotransmitters and Fatigue**: Various neurotransmitters have been studied for their potential role in fatigue. The documents mention several, but the key ones are dopamine, serotonin, and others. 3. **Specific Effects of Neurotransmitters on Fatigue**: - **Dopamine**: The documents mention that the normally high concentration of dopamine in the basal ganglia is reduced in parkinsonism, and pharmacologic attempts to restore dopaminergic activity alleviate many motor features of the disorder. This suggests dopamine's role in motor function and possibly in fatigue, especially in neurological conditions like Parkinson's disease. - **Serotonin**: The documents discuss the decrease in serotonin levels in depression and how antidepressants work by increasing serotonin levels. This indicates serotonin's role in mood regulation and possibly in fatigue, especially in psychiatric conditions like depression. 4. **Combining the Information**: Given the information about dopamine and serotonin, we can see that both play roles in fatigue, especially in different contexts (motor function in dopamine and mood regulation in serotonin). 5. **Choosing the Correct Answer**: Based on the information, the correct answer is the option that includes both dopamine and serotonin, as they have been shown to influence fatigue through different mechanisms. **Output in JSON format:** {\"step_by_step_thinking\": \"Analyzing the provided documents, we identified dopamine and serotonin as neurotransmitters that have been linked to fatigue development. Dopamine is involved in motor function, particularly in neurological conditions like Parkinson's disease, and serotonin is linked to mood regulation, especially in psychiatric conditions like depression. Therefore, the correct answer is the option that includes both dopamine and serotonin.\", \"answer_choice\": \"D\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_1838",
            "title": "InternalMed_Harrison",
            "content": "of chronic fatigue syndrome as well as cancer-associated fatigue. Graded exercise therapy in which physical exercise, most typically walking, is gradually increased with attention to target heart rates to avoid overexertion, was shown to modestly improve walking times and self-reported fatigue measures in patients in the United Kingdom with chronic fatigue syndrome in the large 2011 randomized controlled PACE trial. Psychostimulants such as amphetamines, modafinil, and armodafinil can help increase alertness and concentration and reduce excessive daytime sleepiness in certain clinical contexts, which may in turn help with symptoms of fatigue in a minority of patients, but they have generally proven to be unhelpful in randomized trials for treating fatigue in posttraumatic brain injury, Parkinson\u2019s disease, and MS."
        },
        {
            "id": "Neurology_Adams_3975",
            "title": "Neurology_Adams",
            "content": "The Clinical Significance of Fatigue"
        },
        {
            "id": "Neurology_Adams_3982",
            "title": "Neurology_Adams",
            "content": "Fatigue as a Symptom of Psychiatric Illness"
        },
        {
            "id": "Neurology_Adams_3991",
            "title": "Neurology_Adams",
            "content": "Many states of disordered autonomic function in which static or orthostatic hypotension are features are also associated with a fatigue state. Whether there is in addition a type of central autonomic (hypothalamic) fatigue, aside from the endocrine changes discussed below, is uncertain, but such an entity seems plausible and has been included in models of the illness currently called chronic fatigue syndrome."
        },
        {
            "id": "Neurology_Adams_3972",
            "title": "Neurology_Adams",
            "content": "Fatigue has three basic meanings as experienced in daily life: (1) biochemical and physiologic changes in muscles and a reduced capacity to generate force manifest as weakness, or asthenia; (2) a disorder in behavior, taking the form of a reduced output of work or a lack of endurance; and (3) a subjective feeling of tiredness and the mental discomfort that is associated with such an unnatural state for the individual."
        },
        {
            "id": "InternalMed_Harrison_724",
            "title": "InternalMed_Harrison",
            "content": "There are woefully few pharmacologic interventions that target fatigue and weakness. Glucocorticoids can increase energy and enhance mood. Dexamethasone is preferred for its once-a-day dosing and minimal mineralocorticoid activity. Benefit, if any, usually is seen within the first month. Psychostimulants such as dextroamphetamine (5\u201310 mg PO) and methylphenidate (2.5\u20135 mg PO) may also enhance energy levels, although a randomized trial did not show methylphenidate beneficial compared with placebo in cancer fatigue. Doses should be given in the morning and at noon to minimize the risk of counterproductive insomnia. Modafinil, developed for narcolepsy, has shown some promise in the treatment of severe fatigue and has the advantage of once-daily dosing. Its precise role in fatigue at the end of life has not been determined. Anecdotal evidence suggests that L-carnitine may improve fatigue, depression, and sleep disruption. Similarly, some studies suggest ginseng can reduce fatigue."
        },
        {
            "id": "Neurology_Adams_7287",
            "title": "Neurology_Adams",
            "content": "Unusually severe fatigue is another peculiar symptom of MS; it is often transient and more likely to occur when there is fever or other evidence of disease activity but it can be a persistent complaint and a source of considerable distress. Depression may play a role in these recalcitrant cases, although the response to pharmacologic agents suggests that these 2 aspects of the disease are dissociable. Thus, antidepressants often do not improve fatigue, whereas drugs that alleviate fatigue, such as modafinil and amantadine, do not function as antidepressants."
        },
        {
            "id": "Neurology_Adams_4011",
            "title": "Neurology_Adams",
            "content": "At the present time, the status of the chronic fatigue syndrome is undetermined. The possibility of an obscure endocrine, metabolic or immunologic derangement secondary to a viral infection cannot be dismissed, as discussed by Swartz, but the majority of cases lack such a history and no evidence of a virologic cause has so far held up. Certainly, high levels of cytokines, such as occur after many types of illness and with cancer, and some of the numerous endocrine aberrations are capable of causing fatigue and lethargy. From a neurologic perspective, the hypothalamus is the structure most implicated by the loss of endurance and the presence of associated symptoms such as orthostatic intolerance, tachycardia and some of the endocrine changes enumerated later in the chapter. Treatment, largely unsatisfactory, is discussed further on. Differential Diagnosis of Fatigue"
        },
        {
            "id": "Neurology_Adams_3990",
            "title": "Neurology_Adams",
            "content": "Not surprisingly, many neurologic diseases that are characterized by difficulty engaging the muscles (Parkinson disease is the main example). Muscles partially paralyzed by a stroke feel tired and may cause an overall fatigue state. The distinguished neuroanatomist A. Brodal gave an interesting account of his own stroke and its effects on muscle power. Fatigue is often a major complaint of patients with multiple sclerosis; its cause is unknown, although the effect of cytokines circulating in the cerebrospinal fluid has been postulated. The depression that follows stroke or myocardial infarction frequently presents with the complaint of fatigue rather than other signs of mood disorder. Inordinate fatigue is a common complaint among patients with postconcussive syndrome (see Chap. 34). These central fatigue states and their possible mechanisms, almost all speculative, have been discussed by Chaudhuri and Behan."
        },
        {
            "id": "Neurology_Adams_2848",
            "title": "Neurology_Adams",
            "content": "Yet another unique form of coma is that produced by inhalation anesthetics. The effects of general anesthesia had for many years been attributed to changes in the physical chemistry of neuronal membranes. More recently, it has been recognized that interactions with ligand-gated ion channels, particularly gamma-aminobutyric acid (GABA)-A receptors and alterations in neurotransmitter function are a more likely mechanism of anesthesia-induced unconsciousness. An extensive summary of what is known about the metabolic neurochemistry of anesthetics has been given by Campagna and colleagues and by Brown and coworkers; it emphasizes the changes in neurotransmitter function rather than alterations in membrane fluidity but still do not give a unified theory of the effects of these agents, partly because different classes of drug act at different sites. Inhalation anesthetics are unusual among coma-producing drugs in respect to the sequence of inhibitory and excitatory effects that they produce"
        },
        {
            "id": "InternalMed_Harrison_719",
            "title": "InternalMed_Harrison",
            "content": "etIology The multiple causes of fatigue in the terminally ill can be categorized as resulting from the underlying disease; from disease-induced factors such as tumor necrosis factor and other cytokines; and from secondary factors such as dehydration, anemia, infection, hypothyroidism, and drug side effects. Apart from low caloric intake, loss of muscle mass and changes in muscle enzymes may play an important role in fatigue of terminal illness. The importance of changes in the CNS, especially the reticular activating system, have been hypothesized based on reports of fatigue in patients receiving cranial radiation, experiencing depression, or having chronic pain in the absence of cachexia or other physiologic changes. Finally, depression and other causes of psychological distress can contribute to fatigue."
        },
        {
            "id": "Physiology_Levy_1411",
            "title": "Physiology_Levy",
            "content": "from a specialized compartment, a localized increase in [ADP], extracellular elevation of [K+], and generation of oxygen free radicals, have also been implicated in various forms of exercise-induced muscle fatigue. Finally, the central nervous system contributes to fatigue, especially in how fatigue is perceived by the individual."
        },
        {
            "id": "InternalMed_Harrison_31568",
            "title": "InternalMed_Harrison",
            "content": "No, 4. Physically I feel exhausted Yes, that is true that is not true Scoring: Yes, 1, 2 and 4: 7 6 5 4 that is true FIGurE 464e-1 Shortened fatigue questionnaire. in cytokine production, and shifts in lymphocyte subsets have been described. None of these immune findings appears in most patients, nor does any correlate with the severity of CFS. In theory, symptoms of CFS could result from excessive production of a cytokine, such as interleukin 1, that induces asthenia and other flulike symptoms; however, compelling data in support of this hypothesis are lacking. There is some evidence that CFS patients have mild hypocortisolism, the degree of which is associated with a poorer response to CBT. Discrepancies in perceived and actual cognitive performance are consistent findings in patients with CFS."
        },
        {
            "id": "InternalMed_Harrison_1840",
            "title": "InternalMed_Harrison",
            "content": "Acute fatigue significant enough to require medical evaluation is more likely to lead to an identifiable medical, neurologic, or psychiatric cause than unexplained chronic fatigue. Evaluation of unexplained chronic fatigue most commonly leads to diagnosis of a psychiatric condition or remains unexplained. Identification of a previously undiagnosed serious or life-threatening culprit etiology is rare on longitudinal follow-up in patients with unexplained chronic fatigue. Complete resolution of unexplained chronic fatigue is uncommon, at least over the short term, but multidisciplinary treatment approaches can lead to symptomatic improvements that can substantially improve quality of life. neurologic Causes of weakness and Paralysis Michael J. Aminoff Normal motor function involves integrated muscle activity that is modulated by the activity of the cerebral cortex, basal ganglia, cer-30154"
        },
        {
            "id": "Neurology_Adams_4063",
            "title": "Neurology_Adams",
            "content": "Kahn E: Psychopathic Personalities. New Haven, CT, Yale University Press, 1931. Lader M: The nature of clinical anxiety in modern society. In: Spielberger CD, Sarason IG (eds): Stress and Anxiety. Vol 1. New York, Halsted, 1975, pp 3\u201326. Lesch KP, Bengel D, Jeils A, et al: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory system. Science 274:1527, 1996. Lloyd AR, Gandevia SC, Hales JP: Muscle performance: voluntary activation, twitch properties, and perceived effort in normal subjects and patients with chronic fatigue syndrome. Brain 114:85, 1991. McDougall W: Outlines of Abnormal Psychology. New York, Scribners, 1926. Rosen G: Emotions and sensibility in ages of anxiety: a comparative historical review. Am J Psychiatry 124:771, 1967. Rowe PC, Bou-Holaigah I, Kan JS, et al: Is neurally mediated hypotension an unrecognized cause of chronic fatigue? Lancet 345:623, 1995."
        },
        {
            "id": "InternalMed_Harrison_31696",
            "title": "InternalMed_Harrison",
            "content": "Diurnal variations in symptom severity and alterations in circadian rhythmicity of a number of neurochemical and neurohumoral factors suggest that biologic differences may be secondary to a primary defect in regulation of biologic rhythms. Patients with major depression show consistent findings of a decrease in rapid eye movement (REM) sleep onset (REM latency), an increase in REM density, and, in some subjects, a decrease in stage IV delta slow-wave sleep. Although antidepressant drugs inhibit neurotransmitter uptake within hours, their therapeutic effects typically emerge over several weeks, implicating adaptive changes in second messenger systems and transcription factors as possible mechanisms of action. The pathogenesis of depression is discussed in detail in Chap. 465e. Treatment planning requires coordination of short-term strategies to induce remission combined with longer term maintenance designed to prevent recurrence. The most effective intervention"
        },
        {
            "id": "Physiology_Levy_1454",
            "title": "Physiology_Levy",
            "content": "Burr AR, Molkentin JD. Genetic evidence in the mouse solidifies the calcium hypothesis of myofiber death in muscular dystrophy. Cell Death Differ. 2015;22:1402-1412. oxidative capacity of all involved motor units. Training regimens cannot alter fiber type or the expression of myosin isoforms. 10. Muscle fatigue during exercise is not due to depletion of ATP. The mechanism or mechanisms underlying exercise-induced fatigue are not known, although the accumulation of various metabolic products (lactate, Pi, ADP) has been implicated. In view of the importance of preventing depletion of myoplasmic ATP, which would affect the viability of the cell, it is likely that multiple mechanisms may have been developed to induce fatigue and hence lower the rate of ATP hydrolysis before the individual risks injury or death of the skeletal muscle cell. 11."
        },
        {
            "id": "Neurology_Adams_7381",
            "title": "Neurology_Adams",
            "content": "General Measures in the Treatment of MS Fatigue, a common complaint of MS patients, particularly in relation to acute attacks, responds to some extent to amantadine (100 mg morning and noon), modafinil (200 to 400 mg/d), pemoline (20 to 75 mg each morning), methylphenidate, or dextroamphetamine. For depression associated with the disease, there does not seem to be any superior antidepressant and donepezil has not been found to be helpful for cognitive problems. Agents such as 4-aminopyridine improve conduction through demyelinated central nerve fibers by blocking potassium channels. In some patients these drugs have shown measureable improvements in gait. They are pro-convulsant and should be avoided in individuals at risk of seizures."
        },
        {
            "id": "Neurology_Adams_4781",
            "title": "Neurology_Adams",
            "content": "With respect to the neurotransmitters, it is generally agreed that the concentrations of acetylcholine, norepinephrine, and dopamine decline in the course of normal aging. Also, the concentration of gamma-aminobutyric acid (GABA) has been shown to decline with age, particularly in the frontal cortex (Spokes et al). Analyses of postmortem human and animal brains have failed to demonstrate a decline with age in the concentration of serotonin or its metabolites (McEntee and Crook). Accurate assessment of other neurotransmitters has been more difficult because of their marked lability in postmortem material. Data from experiments in rats suggest that the glutamate content of the brain and the number of N-methyl-d-aspartate (NMDA) receptors diminish with age, but the functional significance of this finding is unclear. Unlike the case in Alzheimer disease, normal aging is associated with only slight and inconsistent abnormalities of cholinergic innervation of the hippocampus and cortex."
        },
        {
            "id": "Pharmacology_Katzung_2980",
            "title": "Pharmacology_Katzung",
            "content": "The normally high concentration of dopamine in the basal ganglia of the brain is reduced in parkinsonism, and pharmacologic attempts to restore dopaminergic activity with levodopa and dopamine agonists alleviate many of the motor features of the disorder. An alternative but complementary approach has been to restore the normal balance of cholinergic and dopaminergic influences on the basal ganglia with antimuscarinic drugs. The pathophysiologic basis for these therapies is that in idiopathic parkinsonism, there is a loss of dopaminergic neurons in the substantia nigra that normally inhibit the output of GABAergic cells in the corpus striatum (Figure 28\u20132). Drugs that induce parkinsonian syndromes either are dopamine receptor antagonists (eg, antipsychotic agents; see Chapter 29) or lead to the destruction of the dopaminergic nigrostriatal neurons (eg, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine [MPTP]; see below). Various other neurotransmitters, such as norepinephrine, are also"
        },
        {
            "id": "Neurology_Adams_11150",
            "title": "Neurology_Adams",
            "content": "to mutations in the cytochrome b gene of the mitochondrial DNA (Andreu et al). The subject of fatigue as a physiologic phenomenon and as a clinical feature of many psychiatric and medical diseases, including those that are predominantly myopathic, is considered fully in Chap. 23."
        },
        {
            "id": "Neurology_Adams_3973",
            "title": "Neurology_Adams",
            "content": "The decreased productivity and capacity for work, which is a direct consequence of fatigue, has been investigated by industrial psychologists. Their findings demonstrate the importance of motivational factors on work output, whether the effort is of physical or mental type. Quite striking are individual constitutional differences in energy and capacity for work, which vary greatly, just as do differences in temperament. What should be emphasized for neurologic practice is that in the majority of persons complaining of fatigue, one does not find muscle fatigue or weakness. This may be difficult to prove, for many such individuals are disinclined to exert full effort in tests of peak power of muscle contraction or in endurance of muscular activity. Contrariwise, fatigue that is so often correctly attributed to psychologic causes may also be a manifestation of medical diseases such as anemia, occult cancer, and chronic infection of inflammatory processes or of neurologic disorders of"
        },
        {
            "id": "Physiology_Levy_1413",
            "title": "Physiology_Levy",
            "content": "Most persons tire and cease exercise long before the motor unit fatigues. General physical fatigue may be defined as a homeostatic disturbance produced by work. The basis for the perceived discomfort (or even pain) probably involves many factors. These factors may include a decrease in plasma glucose levels and accumulation of metabolites. Motor system function in the central nervous system is not impaired. Highly motivated and trained athletes can withstand the discomfort of fatigue and may exercise to the point at which some motor unit fatigue occurs. Part of the enhanced performance observed after training involves motivational factors."
        },
        {
            "id": "Neurology_Adams_3971",
            "title": "Neurology_Adams",
            "content": "wars, it has become a key element of the posttraumatic stress disorders. The common clinical antecedents and accompaniments of fatigue, its significance, and its physiologic and psychologic bases are best understood by considering the effects of fatigue on the normal individual."
        },
        {
            "id": "Neurology_Adams_4064",
            "title": "Neurology_Adams",
            "content": "Rowe PC, Bou-Holaigah I, Kan JS, et al: Is neurally mediated hypotension an unrecognized cause of chronic fatigue? Lancet 345:623, 1995. Roy-Byrne P, Craske MG, Stein MB: Panic disorder. Lancet 368:1023, 2006. Samii A, Wassermann EM, Ikoma K, et al: Decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue or depression. Neurology 47:1410, 1996. Shorter E: From Paralysis to Fatigue: A History of Psychosomatic Illness in the Modern Era. New York, Free Press, 1992. Snaith RP, Taylor CM: Irritability: Definition, assessment, and associated factors. Br J Psychiatry 147:127, 1985. Southwick SM, Krystal JH, Morgan CA, et al: Abnormal noradrenergic function in post traumatic stress disorder. Arch Gen Psychiatry 50:266, 1993. Stein MB, Sareen J: Generalized anxiety disorder. New Engl J Med 373:2059, 2015. Straus SE: The chronic mononucleosis syndrome. J Infect Dis 157:405, 1988."
        },
        {
            "id": "Neurology_Adams_12173",
            "title": "Neurology_Adams",
            "content": "On the histologic level, several studies have shown a depletion of and changes in the pyramidal neurons of the CA3 region of the hippocampus in both depression and stress, but the meaning of these findings is unclear (Sapolsky). They are referred to later in relation to neurogenesis (the appearance in adults of new neurons) in the temporal lobe and recovery from depression. These ideas regarding neurogenesis, which are still speculative, are discussed in Chap. 28. Interestingly, in a rodent model of depression, neurogenesis was required for the beneficial effects of antidepressants to take place (Santarelli). Based in part on this observation, a relationship has been suggested between depressive illness and the later development of dementia. The reviews of Starkstein (1987, 1991) and Robinson, and that of Belmaker and Agam mentioned earlier, may be consulted for further information on anatomic lesions that cause changes in affect. Evolving work on alterations in the brain connectome"
        },
        {
            "id": "Neurology_Adams_3986",
            "title": "Neurology_Adams",
            "content": "Also, sleep is disturbed, with a tendency to early morning waking, so that such persons are at their worst in the morning, both in spirit and in energy output. Their tendency is to improve as the day wears on, and they may even feel fairly normal by evening. Severe fatigue that causes the patient consistently to go to bed right after dinner and makes all mental activity effortful should suggest an associated depression. It may be difficult to decide whether the fatigue is a primary manifestation of the disease or secondary to a lack of interest."
        },
        {
            "id": "InternalMed_Harrison_31567",
            "title": "InternalMed_Harrison",
            "content": "How have you felt during the last two weeks? Please rate all four statements and per statement check the box that reflects your situation best. No, 1. I feel tired Yes, that is not true that is true No, 2. I tire easily Yes, that is true that is not true No, 3. I feel fit Yes, that is true that is not true No, 4. Physically I feel exhausted Yes, that is true that is not true Scoring: Yes, 1, 2 and 4: 7 6 5 4 that is true FIGurE 464e-1 Shortened fatigue questionnaire."
        },
        {
            "id": "InternalMed_Harrison_1817",
            "title": "InternalMed_Harrison",
            "content": "be expected for the associated trigger. Fatigue should be distinguished from muscle weakness, a reduction of neuromuscular power (Chap. 30); most patients complaining of fatigue are not truly weak when direct muscle power is tested. By definition, fatigue is also distinct from somnolence and dyspnea on exertion, although patients may use the word fatigue to describe those two symptoms. The task facing clinicians when a patient presents with fatigue is to identify an underlying cause if one exists and to develop 152 a therapeutic alliance, the goal of which is to spare patients expensive and fruitless diagnostic workups and steer them toward effective therapy."
        },
        {
            "id": "Neurology_Adams_12175",
            "title": "Neurology_Adams",
            "content": "It has been evident for several years that the biogenic monoamines (norepinephrine, serotonin, and dopamine) are in some way involved in the biology of depression. However, most of the neurochemical theories of depression suffer from the weakness that they have been the result of backward reasoning from the effects of antidepressants on various neurotransmitters to the putative mechanisms of the disease. Following the observations that the tricyclic antidepressants and the monoamine oxidase (MAO) inhibitors exerted their effect by increasing norepinephrine and serotonin at central adrenergic receptor sites in the limbic system and hypothalamus and that depression-provoking drugs (such as reserpine) deplete biogenic amines at these sites, it was proposed that naturally occurring depressions might be associated with a deficiency of these substances. Furthermore, depressed patients and their first-degree relatives, as well as healthy individuals, develop a depressed mood after dietary"
        },
        {
            "id": "InternalMed_Harrison_31566",
            "title": "InternalMed_Harrison",
            "content": "The pathophysiology of CFS is unclear. Neuroimaging studies have found that CFS is associated with reduced gray matter volume, which in turn is associated with a decline in physical activity; these changes have been partially reversed following cognitive behavioral therapy (CBT). In addition, functional MRI data have suggested that abnormal patterns of activation correlate with self-reported problems with information processing. Neurophysiologic studies have shown altered CNS activation patterns during muscle contraction. Evidence for immunologic dysfunction is inconsistent. Modest elevations in titers of antinuclear antibodies, reductions in immunoglobulin subclasses, deficiencies in mitogen-driven lymphocyte proliferation, reductions in natural killer cell activity, disturbances How have you felt during the last two weeks? Please rate all four statements and per statement check the box that reflects your situation best."
        },
        {
            "id": "Neurology_Adams_4445",
            "title": "Neurology_Adams",
            "content": "Alterations in blood volume and pressure also affect vasopressin release through neural mechanisms originating in the baroand mechanoreceptors of the aortic arch, carotid sinus, and right atrium. Afferent signals from these regions are conveyed in the vagus and glossopharyngeal nerves, which synapse in the nucleus of the tractus solitarius; the precise pathways leading to the hypothalamus have not been delineated, however. With severe hypotension, ADH release will continue even if there is a low serum osmolality; the effects of blood pressure predominate over osmolarity as a stimulus. Vasopressin secretion is also influenced by nonosmotic factors. Nausea, for example, is associated with a rise in the levels of the hormone, as much as 100-fold. Hypoglycemia also has an effect, but less pronounced. Drugs such as morphine, nicotine, alcohol, and certain chemotherapeutic agents (cyclophosphamide) also cause release of the stored peptide. Pain, emotional stress, and exercise have long been"
        }
    ],
    "scores": [
        0.03390407843224686,
        0.028108273012175167,
        0.027802307363623414,
        0.027796495956873314,
        0.02765014583607108,
        0.02660188070635832,
        0.024748343944146177,
        0.02381345944441643,
        0.022159279485864283,
        0.021995236773954863,
        0.018608274190756446,
        0.01779500158177792,
        0.017542515703998774,
        0.01748358528019545,
        0.017345794392523366,
        0.017195767195767195,
        0.01655719759168035,
        0.016464699683877766,
        0.01630151278038602,
        0.0161509900990099,
        0.01598481136697697,
        0.01595677050222505,
        0.01579338535860275,
        0.015621370499419281,
        0.015324325905129556,
        0.015211104684788895,
        0.015073212747631352,
        0.015051208057488824,
        0.014546548956661316,
        0.01439363005308289,
        0.01422882672882673,
        0.014041246160596753
    ],
    "execution_time": 13.325348615646362
}